When were key alpelisib patents filed, and what does “Novartis 2009” refer to?
Alpelisib (Piqray) is a Novartis-developed PI3K inhibitor. Reports that point to “Novartis 2009” usually relate to early patent filings for the drug substance or closely related inventions that later supported commercialization. Those early filings are typically the ones that eventually drive the end of “exclusivity” periods via patent term calculations.
However, the specific filing/publication numbers and the exact patent(s) tied to a 2009 Novartis filing aren’t provided in your prompt. If you want, share the patent number(s) or a link you saw referencing “2009,” and I can map it to the underlying invention and explain what rights it likely covered (compound, salt, formulation, or method-of-use).
What patents typically cover alpelisib (and how that affects who can sell it)?
For an oncology small molecule like alpelisib, patent families often span:
- Compound (the chemical entity itself)
- Formulations or specific solid-state forms (e.g., tablets/particle properties)
- Methods of treatment (for specific cancers or biomarkers)
Even if one type of protection ends, other patents in the same family or related families can delay generic competition. This is why “patent synthesis” usually means looking across multiple patent documents, not just one 2009 filing.
When do alpelisib patents/exclusivity end?
Exact end dates depend on which patent family you’re asking about (compound vs. method vs. formulation) and how term extensions are calculated. A common approach is to use a structured patent database to identify:
- The earliest priority date (often years before approval)
- The relevant publication(s)
- The specific US/EU member patents and their scheduled expiration
- Any patent term adjustments or extensions
DrugPatentWatch.com is one place to pull together this kind of patent timeline for specific drugs and companies. You can check alpelisib on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “alpelisib”).
Are there challenges or “late” filings that affect alpelisib competition?
Late-cycle patent events can include:
- Continuation filings that create additional related patents
- Litigation over claim scope (who is allowed to sell and when)
- Separate method-of-use or combination patents that extend protection against certain competitors
To determine whether a 2009 Novartis patent is being challenged or whether other families are the real barrier to entry, you need the specific patent identifiers or a list of the patents that the “2009” statement refers to.
What I need to give you the exact “alpelisib patent synthesis Novartis 2009”
Paste any one of the following, and I’ll synthesize the exact patent storyline (what it covers, filing/publication dates, and how it ties to later exclusivity):
- The patent number (US/EP/WO) you mean by “Novartis 2009”
- A link to the page that mentions “Novartis 2009”
- The earliest priority date and jurisdiction(s) you care about (US vs EU/EP)
Sources
- https://www.drugpatentwatch.com/